Lactulose regulates gut microbiota dysbiosis and promotes short-chain fatty acids production in acute pancreatitis patients with intestinal dysfunction

Biomed Pharmacother. 2023 Jul:163:114769. doi: 10.1016/j.biopha.2023.114769. Epub 2023 Apr 26.

Abstract

Background: Intestinal dysfunction is one of the common complications in the early stage of acute pancreatitis (AP), which often associates with bad outcome. Lactulose, as a prebiotic, has been widely used to improve gut health, yet its effect on AP is unclear.

Methods: This was a prospective, randomized trial of moderate severe AP patients complicated with intestinal dysfunction. A total of 73 participants were randomly assigned to receive either lactulose or Chinese herb rhubarb for 1 week. The primary efficacy endpoint was the recovery of intestinal function. The serum levels of inflammatory cytokines and gut barrier indexes were examined. The fecal samples from patients before and after treatment were collected. 16 S rRNA gene sequencing analysis was performed to explore the composition of gut microbiota and the amount of short-chain fatty acids (SCFAs) were detected by gas chromatography-mass spectrometry (GC-MS).

Results: The intestinal dysfunction was prominently improved after 7 days of treatment with either lactulose or rhubarb. The serum levels of cytokines and gut permeability index were decreased after treatment, with stronger down-regulated degree in lactulose group than rhubarb. The potential beneficial genus Bifidobacterium was enriched in lactulose group, while pathogenic bacteria including Escherichia-Shigella and Neisseria were abundant in rhubarb group. Of note, the level of SCFAs was remarkably increased after treatment, with higher amount in lactulose group than rhubarb group.

Conclusions: Lactulose could not only restore intestinal function but also regulate gut microbiota and promote the production of SCFAs.

Keywords: Acute pancreatitis; Gut microbiota; Intestinal dysfunction; Lactulose; Short-chain fatty acids.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Cytokines
  • Dysbiosis / drug therapy
  • Dysbiosis / microbiology
  • Fatty Acids, Volatile / analysis
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Intestinal Diseases*
  • Lactulose / therapeutic use
  • Pancreatitis* / drug therapy
  • Prospective Studies

Substances

  • Lactulose
  • Cytokines
  • Fatty Acids, Volatile